This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Results

Authoring team

There was no significant difference between patients treated with the experimental therapy of paclitaxel plus carboplatin and control treatments over a median follow-up period of 51 months. There was no significant difference in the occurrence of the secondary endpoint of progression-free survival.

There were differences in side-effect profiles:

  • paclitaxel plus carboplatin caused more alopecia, fever and sensory neuropathy than carboplatin alone
  • paclitaxel plus carboplatin caused more sensory neuropathy than CAP
  • CAP caused more fever than paclitaxel plus carboplatin

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.